Ask AI
EGFRm NSCLC Brain Metastases

CE / CME

Management of a Patient With EGFR-Mutated NSCLC and Brain Metastases

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: May 04, 2026

Expiration: November 03, 2026

Activity

Progress
1 2
Course Completed

References

  1. Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol. 2022;40:492-516.
  2. Gondi V, Bauman G, Bradfield L, et al. Radiation therapy for brain metastases: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2022;12:265-282.
  3. Schiff D, Messersmith H, Brastianos PK, et al. Radiation therapy for brain metastases: ASCO guideline endorsement of ASTRO guideline. J Clin Oncol. 2022;40:2271-2276.
  4. Gubens MA, Wakelee HA. Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis. Lung Cancer: Targets and Therapy. 2010;2010:63-76.
  5. Datopotamab deruxtecan [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc; February 2025.
  6. Ahn M-J, Lisberg A, Goto Y, et al. A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC. J Thoracic Oncol. 2025;20:1669-1682.
  7. Pons-Tostivint E, Okamoto I, Ahn M-J, et al. Intracranial efficacy of datopotamab deruxtecan in patients with advanced/metastatic NSCLC in TROPION-Lung01. Presented at: 2025 IASLC WCLC Congress; September 6-9, 2025. Abstract OA10.01.